Search - tctmd.com

Displaying 121 - 140 of 4671

Sort: Relevancy | Date

Presentation TCT 2025

Let’s Get Comfortable: Cath Lab Ergonomics and Radiation Safety

Presenter: David G. Rizik

October 25, 2025

Presentation TCT 2025

TCT 1318: Safety and short term outcome of coiling of septal perforators in patient with hypertrophic obstructive cardiomyopathy

Presenter: Puneet Aggarwal

October 25, 2025

Presentation TCT 2025

TCT 11: Safety and outcome of wire assisted mitral valve crossing in difficult left ventricular entry of balloon in percutaneous transluminal mitral balloon valvotomy.

Presenter: Puneet Aggarwal

October 25, 2025

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

News Features

Imperfect Evidence: How Strong Is the Case for Transcatheter Tricuspid Valve Interventions?

October 22, 2025

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

News Daily News

Oral Semaglutide Gets FDA Approval for CV Event Reduction in High-risk Diabetes Patients

October 22, 2025

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

News Daily News

Bax24: Baxdrostat Successful Again, This Time in Resistant Hypertension

October 07, 2025

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

News Daily News

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

October 02, 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

News Conference News HFSA 2025

Lowering Novel Biomarker, GDF-15, Raises HF Event Rate: GARDEN-TIMI 74

Yael L. Maxwell

September 30, 2025

TCTMD’s Top 10 Most Popular Stories for September 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2025

Michael O'Riordan

September 30, 2025

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

News Industry News

Positive 3-Year Results from FIRE Trial Demonstrate Supraflex Cruz’s Safety and Efficacy in Elderly Heart Attack Patients

September 15, 2025

BEAT PAROX-AF: Pulsed-Field Ablation Not Superior to Radiofrequency

News Conference News ESC 2025

BEAT PAROX-AF: Pulsed-Field Ablation Not Superior to Radiofrequency

September 09, 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

News Conference News ESC 2025

ESC Guidelines Update Clarifies Pregnancy Risks and Choices in Women With CVD

September 09, 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

News Conference News ESC 2025

Renewed Questions About Safety of Paclitaxel Devices in PAD: SWEDEPAD

September 05, 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

News Conference News ESC 2025

DAPT’s Role After CABG Questioned: TACSI and TOP-CABG

September 05, 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

September 01, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

News Conference News ESC 2025

Olezarsen Brings Moderately High Triglycerides Under Control: ESSENCE-TIMI 73b

August 31, 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

News Conference News ESC 2025

BaxHTN: Baxdrostat Lowers BP in Uncontrolled and Resistant Hypertension

August 31, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.